Using antifibrinolytics in the peripartum period - concern for a hypercoagulable effect?
Repository Usage Stats
INTRODUCTION: Although antifibrinolytic agents are used to prevent and treat hemorrhage, there are concerns about a potential increased risk for peripartum venous thromboembolism. We sought to determine the impact of tranexamic acid and ɛ-aminocaproic acid on in vitro clotting properties in pregnancy. METHODS: Blood samples was obtained from healthy pregnant, obese, and preeclamptic pregnant women (n = 10 in each group) prior to delivery as well as from healthy non-pregnant controls (n = 10). Maximum clot firmness (MCF) and clotting time (CT) were measured using rotation thromboelastometry in the presence of tranexamic acid (3, 30, or 300 μg/mL) or ɛ-aminocaproic acid (30, 300, or 3000 μg/mL). ANOVA and regression analyses were performed. RESULTS: Mean whole blood MCF was significantly higher in healthy pregnant vs. non-pregnant women (66.5 vs. 57.5 mm, p < 0.001). Among healthy pregnant women, there was no significant difference between mean MCF (whole blood alone, and with increasing tranexamic acid doses = 66.5, 66.1, 66.4, 66.3 mm, respectively; p = 0.25) or mean CT (409, 412, 420, 424 sec; p = 0.30) after addition of tranexamic acid. Similar results were found using ɛ-aminocaproic acid. Preeclamptic women had a higher mean MCF after the addition of ɛ-aminocaproic acid and tranexamic acid (p = 0.05 and p = 0.04, respectively) compared to whole blood alone. CONCLUSIONS: Pregnancy is a hypercoagulable state, as reflected by an increased MCF compared to non-pregnant women. Addition of antifibrinolytic therapy in vitro does not appear to increase MCF or CT for non-pregnant, pregnant, and obese women. Whether antifibrinolytics are safe in preeclampsia may require further study.
Published Version (Please cite this version)10.3233/NPM-16139
Publication InfoAhmadzia, HK; Grotegut, Chad Aaron; Hoffman, Maureane Richardson; James, Andra Hohler; Lockhart, EL; Murtha, Amy; ... Welsby, Ian James (2017). Using antifibrinolytics in the peripartum period - concern for a hypercoagulable effect?. J Neonatal Perinatal Med. 10.3233/NPM-16139. Retrieved from http://hdl.handle.net/10161/13911.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
More InfoShow full item record
Associate Professor of Obstetrics and Gynecology
Professor of Pathology
The blood coagulation system is a delicately balanced homeostatic mechanism. Inappropriate clotting is a major cause of morbidity and mortality, resulting in strokes, heart attacks, thrombophlebitis and pulmonary embolism. My research is directed toward understanding basic mechanisms in hemostasis, and the connections between inflammation/immunity and coagulation responses to injury. We are also committed to translating our basic finding into clinical practice.We have developed
Consulting Professor in the Department of Obstetrics and Gynecology
I am an OB-GYN and a specialist in maternal-fetal medicine and high-risk obstetrics. My research and publications pertain mainly to the care of women with blood disorders (thrombosis and thrombophilia), bleeding disorders (including von Willebrand disease), platelet disorders (including ITP), and sickle cell disease.
Professor of Obstetrics and Gynecology
Dr. Amy Murtha is a Professor in the Department of Obstetrics and Gynecology and Department of Pediatrics, and past Vice Chair for Research in Obstetrics and Gynecology. After graduating from the Medical College of Pennsylvania in 1992 she completed her residency in OB-GYN and fellowship in Maternal Fetal Medicine (MFM) at Duke University then joined the faculty at Duke in 1998. Dr. Murtha served as interim Chair for the Department of OB-GYN and Fellowship Director for the mater
Associate Professor of Obstetrics and Gynecology
Dr. Geeta Swamy, MD, became Vice Chair for Research and Faculty Development in the Department of Obstetrics and Gynecology on March 1, 2018. In this dual role, Dr. Swamy oversees strategic development and administration of the Department’s basic, translational and clinical research programs, as well as implements and oversees programs to support development and mentorship for all faculty at all levels. Dr. Swamy has dedicated her career to advancing research in women’s he
Professor of Anesthesiology
As a practicing cardiothoracic anesthesiologist, I have contributed to the better understanding of the management and of perioperative thrombosis (particularly HIT). This has been as a Duke site PI for the Rare Thrombotic Diseases Consortium led by Dr T.L Ortel and a clinical collaborator with the basic and translational science approach to HIT led by Dr G Arepally. I have also championed novel approaches to dealing with perioperative HIT such as plasmaperesis.Similarly, I have be
Alphabetical list of authors with Scholars@Duke profiles.